Grants for For profit organizations other than small businesses - Federal

The "ROSES 2024: A.16 Cryospheric Science" grant is a funding opportunity by NASA's Science Mission Directorate for research and technology projects in space and Earth sciences, with a focus on cryospheric science, and is open to various types of organizations both domestic and foreign.

This funding opportunity supports the development and testing of cancer-related interventions through real-world clinical trials, particularly targeting diverse populations and addressing health disparities in the United States.

With this solicitation, OJJDP seeks to support the development and dissemination of translational tools and resources current knowledge about what works packaged in accessible, comprehensible, actionable form for use by everyday youth serving (nonresearcher) practitioners, and lay persons to effect and sustain positive change on key topics spanning the juvenile justice continuum in order to improve the juvenile justice system and prevent juvenile delinquency.

This funding opportunity supports U.S. institutions conducting research to improve health and performance for astronauts during human space exploration missions.

This Notice of Intent to Publish is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects for the following Notice of Funding Opportunity (NOFO), which is expected to be published in January 2024, with an anticipatedapplication receipt date in May 2024. The Brain Research through Advancing Innovative Neurotechnologies(BRAIN) Initiative intends to promote a new initiative by publishing a NOFO to solicit applications that would support development and preclinical testing, beginning withproof of concept,of next-generation recording and/or modulation devices for human use to further our understanding of the human central nervous system and treat nervous system disorders. This NOFO will utilize the R18 activity code. Details of the planned NOFO are provided below.

The FY24 VRP MCRA is intended to support patient-oriented vision injury research and develop research expertise of highly motivated military or civilian clinicians in training. Research supported by the MCRA can be a standalone study of high impact to vision injury care or the generation of clinical research data in preparation for a more expansive study.Each MCRA must be led by an established clinician or Ph.D. clinical scientist who will serve as Principal Investigator (PI) of the award. Key personnel must include a clinician in training (e.g., a fellow, resident, junior clinician, clinician in a Ph.D. program). The clinician in training should have sufficient time remaining in their training program to complete the research proposed under the MCRA. The clinician in training will conduct the proposed research under the mentorship of the PI, with support from supporting personnel as appropriate. While additional junior scientists or clinicians may participate in the research, only one clinician in training may be designated as mentee. A Letter of Organizational Support and Mentee Eligibility, signed by the Department Chair or appropriate organization official, and a Letter of Commitment, signed by the mentee, should be submitted as part of Attachment 2: Supporting Documentation.For the purposes of this award mechanism, clinical research is defined as research conducted with human subjects or research on material of human origin, such as tissues or specimens or data obtained from human subjects. Documentation of Institutional Review Board (IRB)/ Ethics Committee (EC) approval or exemption by December 1, 2024, is required for an MCRA application to be considered for funding. See Attachment 2: Supporting Documentation for additional detail.The MCRA may not be used to conduct preclinical research (including animal research) or clinical trials.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Studies that retrospectively analyze data generated from previously conducted clinical trial(s) are not considered a clinical trial.

The United States Agency for International Development (USAID) is issuing this Broad Agency Announcement (BAA) to seek participants to co-create, co-design, co-invest, and collaborate on creating, piloting, and scaling innovative research and development interventions utilizing innovative health practices to help reduce disease and mortality rates worldwide. USAID invites organizations and companies to submit an Expression of Interest (EOI) and participate in generating novel tools and approaches that accelerate and sustain improved health outcomes in low-and-middle-income countries (LMICs). The intent of the BAA is to allow co-creation and co-design to the maximum extent to create high quality, effective partnerships with great efficiency in time and resources. USAID is seeking new applications of research development, science, partnerships, and innovative practices in global health that provide the best value to the Government. USAID will invite selected for-profit and non-profit, public and private organizations, as detailed below, to co-create innovative research and development (R) solutions to the Problem and Challenge Statements stated in this BAA, including those organizations that have ideas, expertise, resources, and/or funding to add to potential solutions. In particular, this BAA welcomes co-creation from local partners based in LMICs, including the private sector, faith-based organizations, and other non-traditional USAID partners, to increase the presence and voices of local populations in solving their own health challenges.The intent of the BAA is to enable and encourage co-creation and co-design in order to generate high quality ideas and effective partnerships with improved efficiency in time and resources. Other types of collaboration can also include co-investing:Co-Investing: USAID wants to align goals with the partners under this BAA, to facilitate shared responsibility, shared risk, and shared resourcing. Shared resourcing requires that cash and other resources, both tangible and intangible, such as in-kind contributions, expertise, intellectual property, brand value, high-value coordination, and access to key people, places, and information, are directed towards reaching the solution to the Problem/Challenge. Co-investing does not require equal shared resources (such as 1:1 leverage), but rather resource contributions that are appropriate to the specific projects objectives, considering the comparative advantages brought by the participation of each party.

This competition provides financial incentives for U.S.-based manufacturers of solar photovoltaic modules and inverters to achieve environmental certification, enhancing their marketability and sustainability efforts.

This funding opportunity provides financial support for research and evaluation projects aimed at improving malaria control and prevention strategies in Kenya, specifically targeting collaborations with local health institutions.

The overall goal of ProCON Global is to promote open, interoperable, reliable, and secure commercial undersea cable systems around the world. The project will provide technical assistance to key decision-makers, including policymakers, regulators, and technology companies in emerging economies, to promote evaluation processes and investment in secure and trusted vendors when establishing undersea cable network supply chains. Technology companies include telecommunications operators/carriers, major technology and security firms, innovators, and content and cloud providers.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a fundamentally new approach that is significantly more effective than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the program announcement, and not on the amount of the budget.The current program announcement discusses the Breakthrough Award Level 3. Funding Levels 1, 2, and 4 are available under other program announcements (HT942524BCRPBTA12 for Levels 1 and 2 and HT942524BCRPBTA4 for Level 4). The PI is strongly encouraged to review the research scope defined under each funding level as described in the corresponding Breakthrough Award program announcements before submitting the pre-application. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.The following is a general description, although not all-inclusive, of the scope of research projects that would be appropriate to propose under the current program announcement:Funding Level 3: Advanced translational studies with a high degree of project readiness. Where relevant, proof of availability of and access to necessary data, human samples, cohort(s), and/or critical reagents must be provided. If the proposed research would ultimately require U.S. Food and Drug Administration (FDA) involvement, applications must demonstrate availability of, and access to, clinical reagents (e.g., therapeutic molecules) and patient population(s). Applications must state a realistic timeline for near-term clinical investigation. Small-scale clinical trials (e.g., first in human, phase 1/1b) may be appropriate.Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive partnerships between investigators. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. It is expected that funding will be balanced between both PIs unless appropriately justified. New partnerships are encouraged, but not required. The application is expected to describe how the PIs unique expertise combined as a partnership will better address the research question, how the unique expertise that each individual brings to the application is critical for the research strategy and completion of the SOW, and why the work should be done together rather than through separate efforts. To meet the intent of the Partnering PI Option, applicants are discouraged from being named as a Partnering PI on multiple Breakthrough Award Level 3 applications unless they are clearly addressing distinct research questions. Applications where one PI is providing samples, animal models, or investigational agents while the other PI is conducting most or all of the experiments and analyses do not meet the intent of the Partnering PI Option. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission.Personnel: Applications are expected to include an appropriate and robust research team with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the project.Consumer Advocates: Applications are required to include consumer advocate involvement. The research team must include two or more breast cancer consumer advocates, who will be integral throughout the planning and implementation of the research project. Consumer advocates should be involved in the development of the research question, project design, oversight, recruitment, and evaluation, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer, and they should be active in a breast cancer advocacy organization. Their role in the project should be independent of their employment, and they cannot be employees of any of the organizations participating in the application. Their role should be focused on providing objective input on the research and its potential impact for individuals with, or at risk for, breast cancer. The consumer advocates should have a high level of knowledge of current breast cancer issues and the appropriate background and/or training in breast cancer research to contribute to the project.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Breakthrough Award Level 3 should not exceed $4M for applications with a single PI or $5M if applying under the Partnering PI Option. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $13.95M to fund approximately two BCRP Breakthrough Award Level 3 applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity provides financial support for organizations to maintain and enhance a national website that helps the public and law enforcement access information about registered sex offenders across the United States.

This Funding Opportunity Announcement (FOA) is being issued by the Office of Energy Efficiency and Renewable Energy;apos;s (EERE) Advanced Materials and Manufacturing Technologies Office (AMMTO). The goals of this FOA are to advance manufacturing platform technologies in the following specific areas: Platforms for next generation battery manufacturing - focusing on manufacturability and scalability of critical battery components and system architectures as well as the role of machines for battery techonlogies (i.e., sodium-ion batteries (NIBs), flow batteries, and nanolayered films) Smart manufacturing platforms for battery production - developing innovative ways to revolutionize battery prouction by maximizing the benefits of smart manufacturing This FOA will support activities to advance platform techonologies that enable flexible, scalable, and highly controllable battery manufacturing processes. Topics include: 1. Platforms for Next Generation Battery Manufacturing 1.1 Processes and Machines for Sodium-ion Batteries 1.2 Processes and Design for Manufacturability of Flow Batteries 1.3 Scalable Manufacturing of Nanolayered Films for Energy Storage 2. Smart Manufacturing Platforms for Battery Production Please see https://eere-exchange.energy.gov for full funding announcement.

This funding opportunity supports research projects that use genome editing techniques to explore the genetic factors contributing to substance use disorders, encouraging diverse organizations to participate in advancing addiction science.

With this solicitation, OJJDP seeks to select organization(s) to provide training and technical assistance geared toward strengthening prosecution efforts as listed below: Prosecution of cases of child victimization while in custodial care. These are cases in which children or youth report that they have been victimized while in out-of-home placement, whether that is foster care, group home, shelter care, or a custodial setting. These cases are far less likely to result in prosecution than cases in which a child or youth has been victimized while not in out-of-home placement.

This funding opportunity provides financial support to medical examiner and coroner offices for accreditation and to develop forensic pathology fellowships, addressing workforce shortages and improving death investigation standards nationwide.

The anticipated funding opportunity announcement (FOA) aims to support research and development projects under the Vehicle Technologies Office (VTO). The goals include the demonstration of smart charge management for electric vehicles, improvement of 12-volt lead-acid batteries for safety-critical electric vehicle applications, development of strategies to reduce the likelihood of cascading effects of electric vehicle fires, reduction in battery electrode, cell, and pack manufacturing costs, advancement of silicon-based anodes for lithium-ion batteries, and development of high-energy density conversion cathodes. The FOA emphasizes advancing equity, addressing the climate crisis, and achieving net-zero emissions by 2050. Eligible applicants are encouraged to include underrepresented groups and underserved communities in their project teams. The FOA will fund activities related to electric vehicle (EV) technologies, focusing on areas such as smart charge management, safety improvements in EV batteries, cost reduction in battery manufacturing, and the development of advanced battery materials. The Department of Energy aims to drive innovation in clean energy technologies, ensuring environmental justice and inclusion. Specific areas of interest include wide-scale demonstrations of smart charge management, enhancement of safety-critical 12-volt lead-acid batteries, reduction of cascading effects of battery fires, cost reduction in battery manufacturing, and the development of high-energy-density battery components.

This notice announces the opportunity to apply for funding under the Technology-enabled Collaborative Learning Program (TCLP). The purpose of this program is to improve retention of health care providers and increase access to health care services, such as those to address chronic diseases and conditions (including Alzheimers disease), infectious diseases, mental health and substance use disorders, prenatal and maternal health, pediatric care, pain management, palliative care, and other specialty care in rural areas, frontier areas, health professional shortage areas, or medically underserved areas and for medically underserved populations or Native Americans. Recipients will evaluate, develop, and, as appropriate, expand the use of technology-enabled collaborative learning and capacity building models. In this NOFO, the term "technology-enabled collaborative learning and capacity building model" means a distance health education model that connects health care professionals, and particularly specialists, with multiple other health care professionals through simultaneous interactive videoconferencing for the purpose of facilitating case-based learning, disseminating best practices, and evaluating outcomes. This cooperative agreement aligns with HRSAs goals of promoting a health care workforce to address current and emerging needs, improving access to quality health services, achieving health equity, and enhancing population health. The development and acquisition of instructional programming by the TCLP will increase access to quality care using telehealth and innovative technology solutions. The TCLP will also provide training for health care providers and other professionals that provide or assist in the provision of services, including training on best practices for data collection and evaluation activities to study the impact on patient outcomes and health care providers.

Note: Each funding opportunity description is a synopsis of information in the Federal Register application notice. For specific information about eligibility, please see the official application notice. The official version of this document is the document published in the Federal Register. Free Internet access to the official edition of the Federal Register and the Code of Federal Regulations is available on GPO Access at: http://www.access.gpo.gov/nara/index.html. Please review the official application notice for pre-application and application requirements, application submission information, performance measures, priorities and program contact information. For the addresses for obtaining and submitting an application, please refer to our Revised Common Instructions for Applicants to Department of Education Discretionary Grant Programs, published in the Federal Register on December 23, 2024. Purpose of Program: The SEED program, authorized under section 2242 of the Elementary and Secondary Education Act of 1965, as amended (ESEA) (20 U.S.C. 6672), provides funding to increase the number of highly effective educators by supporting the implementation of evidence-based practices that prepare, develop, or enhance the skills of educators. These grants will allow eligible entities to develop, expand, and evaluate practices that can serve as models to be sustained and disseminated. Assistance Listing Number (ALN) 84.423A.

Organizations of State and Local Officials (NOSLO) Program: State Health Services and Financing to fund a national level organization with an in-depth understanding of, and experience with, providing technical assistance and support to State Medicaid Directors and other health care payment officials to assist states in leveraging HRSA programs and collaborating with Medicaid to improve access to quality health care for high need communities. Activities should include but are not limited to fostering collaborations to address maternal health disparities, bolster the health workforce, integrate behavioral health into primary care, and expand access to care for people in high need communities, such as those who live rural areas, are exiting incarceration, have HIV, and youth with unmet behavioral health needs. The successful recipient is expected to provide tailored technical assistance to State Medicaid Directors and other health care payment officials to address HRSAs priorities and maximize the benefits of and potential collaborations with HRSA programs through: Communication and information sharing between HRSA and State Medicaid Directors and other health care payment officials, and Training; data collection, sharing, and analysis; convenings, (e.g., learning exchanges on priority topics); and other activities that enable State Medicaid Directors and other health care payment officials to operate in a responsive, coordinated, and effective manner.